Yıl 2021, Cilt , Sayı , Sayfalar 44 - 48 2021-01-20

Remisyonda olan romatoid artritli hastada tedavi kararı
Treatment decision in patient with rheumatoid arthritis in remission

Ayten YAZICI [1]


Romatoid artrit (RA) erişkinde en sık görülen inflamatuar artrit olup, tedavisinde remisyon veya düşük hastalık aktivitesi hedeflenmektedir. Bu nedenle öncelikle RA’da kalıcı remisyon tanımının ve süresinin kesin olarak belirlenmesi gerekmektedir. Mevcut önerilere göre en az altı aydır remisyonda olan ve sabit dozda hastalık modifiye edici ilaç (DMARD) kullanan hastalarda doz azaltılması önerilmektedir. Özellikle anti-siklik sitrüline peptid sonucu negatif, inflamatuar belirteçleri normal olan ve ultrasonografide aktif inflamasyonu olmayan hastalarda steroid kesildikten sonra biyolojik DMARD dozu veya sıklığının azaltılması, sonrasında konvansiyonel DMARD ile kombine kullanan ve halen remisyonda olanlarda biyolojik DMARD’ın kesilmesi relaps açısından daha güvenli görünmektedir. Tek başına konvansiyonel DMARD kullananlarda ise sadece doz azaltılması önerilmektedir.
Rheumatoid arthritis (RA) is the most common inflammatory disease in adults, and remission or low disease activity is targeted for treatment of RA. Therefore, the definition and duration of sustained remission for RA should be determined precisely. According to current recommendations, dose reduction is recommended in patients who use stable dose disease modifying antirheumatic drugs (DMARD) and have been in remission for at least 6 months. Tapering of biologic DMARD (dose or frequency) after steroid discontinuation may be considered, especially in patients who had negative anti cyclic citrullinated peptide, normal inflammatory markers and no active signal in ultrasonography. In persistent remission, discontinuation of biologic DMARD may be considered if treatment combined with a conventional DMARD. Only tapering is recommended for patients who use conventional DMARD as monotherapy.
  • Gerd RB, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet 2017; 389: 2338-48.
  • Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations fort he management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2016; 76: 960-77.
  • Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016; 68: 1-26.
  • Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016; 75 (8): 1428-37.
  • Smolen SF, Aletaha D, McLnnes IB. Rheumatoid arthritis. Lancet 2016; 388: 2023-38.
  • Aletaha D, Smolen JS. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat Rev Rheumatol 2019; doi: 10.1038/s41584-019-0279-6. (Equb ahead of print)
  • Dubost JJ, Pereira B, Fan A, Soubrier M. Rate of remission among rheumatoid arthritis patients being treated by rheumatologist in routine practice. Joint Bone Spine 2019; doi: 10.1016j/jbspin.2019.03.006. (Equb ahead of print)
  • Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskel Dis 2017; 9: 249-62.
  • Yilmaz-Oner S, Gazel U, Can M, Atagunduz P, Direskeneli H, Inanc N. Predictors and the optimal duration of sustained remission in rheumatoid arthritis. Clin Rheumatol 2019; doi: 10.1007/s10067-019-04654-7. (Equb ahead of print)
  • Lau, CS, Chia F, Dans L, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J of Rheum Dis 2019; 22: 357–75.
  • Lau CS, Chia F, Harrison A, et al. APLAR rheumatoid arthritis treatment recommendations. Int J of Rheum Dis 2015; 18: 685–713.
  • Cefle A, Keser G, Terzioğlu E ve ark. Türkiye Romatoloji Derneği romatoid artrit ulusal tedavi önerileri. Ulus Romatol Derg 2018; 10: 81-4.
  • Baker KF, Skelton AJ, Lendrem DW, et al. Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. J Autoimmun 2019; doi: 10.1016/j.jaut.2019.06.009. (Equb ahead of print)
  • Van den Broke M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol 2012; 30: S35-8. 48 Ege Tıp Dergisi / Ege Journal of Medicine
  • Sanmarti R, Veale DJ, Martin-Mola E, et al. Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open-label trial. Arthritis Rheumatol. 2019; doi: 10.1002/art.40905. (Equb ahead of print)
  • Tanaka Y. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology (Oxford) 2016;55(suppl 2):ii15-ii22.
  • Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015; 74: 389-95.
  • Haschka J, Englbrecht M, Hueber AJ, et al. Relaps rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2016; 75: 45-51.
  • Mangoni AA, Okaily FA, Almoallim H, Rashidi SA, Mohammed RHA, Barbary A. Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature. BMC Rheumatol 2019; doi: 10.1186/s41927-019-0058-7. (Equb ahead of print)
  • Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of BDMARD discontinuation or tapering in rheumatoid arthritis: systemic analysis of the literature and meta-analysis. Ann Rheum Dis 2018; 77: 515-22.
  • Tanaka Y, Hirata S. Is it possible to withdraw biologics from therapy in rheumatoid arthritis? Clin Ther 2013; 35: 2028-35.
  • Tanaka Y, Hirata S. Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis. Drugs 2014; 74 (18): 2129-39.
  • Schlager L, Loiskandl M, Alehata D, Radner D. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatlogy (Oxford) 2019; doi: 10.1093/rheumatology/kez276. (Equb ahead of print).
Birincil Dil tr
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Olgu Sunumu
Yazarlar

Orcid: 0000-0003-2167-4509
Yazar: Ayten YAZICI (Sorumlu Yazar)
Kurum: Kocaeli Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Romatoloji Bilim Dalı, İzmir, Kocaeli, Türkiye
Ülke: Turkey


Tarihler

Başvuru Tarihi : 6 Nisan 2020
Kabul Tarihi : 28 Ağustos 2020
Yayımlanma Tarihi : 20 Ocak 2021

Bibtex @olgu sunumu { etd863635, journal = {Ege Tıp Dergisi}, issn = {1016-9113}, eissn = {2147-6500}, address = {}, publisher = {Ege Üniversitesi}, year = {2021}, volume = {}, pages = {44 - 48}, doi = {10.19161/etd.863635}, title = {Remisyonda olan romatoid artritli hastada tedavi kararı}, key = {cite}, author = {Yazıcı, Ayten} }
APA Yazıcı, A . (2021). Remisyonda olan romatoid artritli hastada tedavi kararı . Ege Tıp Dergisi , Cilt: 60 Özel Sayı: 1 (Romatoloji) , 44-48 . DOI: 10.19161/etd.863635
MLA Yazıcı, A . "Remisyonda olan romatoid artritli hastada tedavi kararı" . Ege Tıp Dergisi (2021 ): 44-48 <http://egetipdergisi.com.tr/tr/pub/issue/59812/863635>
Chicago Yazıcı, A . "Remisyonda olan romatoid artritli hastada tedavi kararı". Ege Tıp Dergisi (2021 ): 44-48
RIS TY - JOUR T1 - Remisyonda olan romatoid artritli hastada tedavi kararı AU - Ayten Yazıcı Y1 - 2021 PY - 2021 N1 - doi: 10.19161/etd.863635 DO - 10.19161/etd.863635 T2 - Ege Tıp Dergisi JF - Journal JO - JOR SP - 44 EP - 48 VL - IS - SN - 1016-9113-2147-6500 M3 - doi: 10.19161/etd.863635 UR - https://doi.org/10.19161/etd.863635 Y2 - 2020 ER -
EndNote %0 Ege Tıp Dergisi Remisyonda olan romatoid artritli hastada tedavi kararı %A Ayten Yazıcı %T Remisyonda olan romatoid artritli hastada tedavi kararı %D 2021 %J Ege Tıp Dergisi %P 1016-9113-2147-6500 %V %N %R doi: 10.19161/etd.863635 %U 10.19161/etd.863635
ISNAD Yazıcı, Ayten . "Remisyonda olan romatoid artritli hastada tedavi kararı". Ege Tıp Dergisi / (Ocak 2021): 44-48 . https://doi.org/10.19161/etd.863635
AMA Yazıcı A . Remisyonda olan romatoid artritli hastada tedavi kararı. ETD. 2021; 44-48.
Vancouver Yazıcı A . Remisyonda olan romatoid artritli hastada tedavi kararı. Ege Tıp Dergisi. 2021; 44-48.
IEEE A. Yazıcı , "Remisyonda olan romatoid artritli hastada tedavi kararı", Ege Tıp Dergisi, ss. 44-48, Oca. 2021, doi:10.19161/etd.863635